Legal Representation
Attorney
Patricia A Wilczynski Brozek
USPTO Deadlines
Next Deadline
2065 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-03-04)
Due Date
March 04, 2031
Grace Period Ends
September 04, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
26 events| Date | Code | Type | Description |
|---|---|---|---|
| Jun 5, 2025 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Mar 4, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Mar 4, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Feb 7, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
| Jan 14, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jan 14, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jan 8, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Dec 19, 2024 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Dec 19, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Dec 19, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Dec 19, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Nov 22, 2024 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Nov 22, 2024 | GNFR | O | FINAL REFUSAL E-MAILED |
| Nov 22, 2024 | CNFR | R | FINAL REFUSAL WRITTEN |
| Nov 12, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Nov 12, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Nov 12, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Aug 25, 2024 | RFNT | P | REFUSAL PROCESSED BY IB |
| Aug 8, 2024 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Aug 8, 2024 | RFRR | P | REFUSAL PROCESSED BY MPU |
| Jul 24, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Jul 23, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jul 23, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| Apr 24, 2024 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Mar 22, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Mar 14, 2024 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical agents affecting metabolism; cardiovascular treatment preparations; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of diseases of the metabolic system; pharmaceutical preparations for the treatment of cardiovascular disease; medicines for the treatment of cardiovascular and cerebrovascular diseases; pills for dizziness symptoms treatment being pharmaceutical preparations for the treatment of dizziness; biological preparations for medical purposes being biological preparations for the treatment of anemia, kidney disease and kidney disorders; cardiovascular agents for medical purposes; drugs for medical purposes being pharmaceutical preparations for the treatment of anemia, kidney disease and kidney disorders; synthetic peptides for pharmaceutical purposes being synthetic peptides for the treatment of anemia, kidney disease and kidney disorders; pharmaceuticals being pharmaceutical preparations for the treatment of anemia, kidney disease and kidney disorders; medicines for human purposes being pharmaceutical preparations for the treatment of anemia, kidney disease and kidney disorders; anemia treatment medicines that stimulate red blood cell production being pharmaceutical preparations for the treatment of anemia; medicines to stimulate red blood cell production being pharmaceutical preparations for the treatment of anemia; pharmaceutical preparations for treatment of chronic kidney disease and anemia; biological preparations for treatment of anemia; biological preparations to stimulate red blood cell production for veterinary and medical purposes being biological preparations for the treatment of anemia; synthetic peptides for pharmaceutical and anemia treatment purposes being synthetic peptides for the treatment of anemia; synthetic peptides for pharmaceutical and kidney disease treatment purposes being synthetic peptides for the treatment of kidney disease
Classification
International Classes
005